ReviewCellular and molecular life sciences : CMLS2010
Chromogranin A: a novel susceptibility gene for essential hypertension.
Review in Cellular and molecular life sciences : CMLS, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Combining a novel ensemble model and multiplex methylation SNaPshot assays for saliva age prediction and cross-platform data analysis.BMC genomics · 2025Article
- A complex role of chromogranin A and its peptides in inflammation, autoimmunity, and infections.Frontiers in immunology · 2025Review
- Age and Sex-related Chromogranin A Gene Polymorphisms and its Association with Metabolic Syndrome Components.Journal of the ASEAN Federation of Endocrine Societies · 2024Article
- Reduction in CgA-Derived CST Protein Level in HTR-8/SVneo and BeWo Trophoblastic Cell Lines Caused by the Preeclamptic Environment.International journal of molecular sciences · 2023Article
- Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation.Basic research in cardiology · 2021Article
- Chromogranin A demonstrates higher expression in preeclamptic placentas than in normal pregnancy.BMC pregnancy and childbirth · 2021Article
- Cerebrospinal Fluid Levels of Chromogranin A in Parkinson's Disease and Multiple System Atrophy.Brain sciences · 2021Article
- Chromogranin A pathway: from pathogenic molecule to renal disease.Journal of hypertension · 2020Article
- Age-dependent increase of oxidative stress regulates microRNA-29 family preserving cardiac health.Scientific reports · 2017Article
- A haplotype variant of the human chromogranin A gene (The Journal of biological chemistry · 2017Article
- Catestatin Gly364Ser Variant Alters Systemic Blood Pressure and the Risk for Hypertension in Human Populations via Endothelial Nitric Oxide Pathway.Hypertension (Dallas, Tex. : 1979) · 2016Article
- MicroRNAs and Endothelial (Dys) Function.Journal of cellular physiology · 2016Review
- The emerging role of non-coding RNA in essential hypertension and blood pressure regulation.Journal of human hypertension · 2015Review
- MicroRNA-22 and promoter motif polymorphisms at the Chga locus in genetic hypertension: functional and therapeutic implications for gene expression and the pathogenesis of hypertension.Human molecular genetics · 2013Article
- Genes involved in systemic and arterial bed dependent atherosclerosis--Tampere Vascular study.PloS one · 2012Article
- The extended granin family: structure, function, and biomedical implications.Endocrine reviews · 2011Review
- Systematic polymorphism discovery after genome-wide identification of potential susceptibility loci in a hereditary rodent model of human hypertension.Blood pressure · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromogranin A (CHGA) is ubiquitously expressed in secretory cells of the endocrine, neuroendocrine, and neuronal tissues. Although this protein has long been known as a marker for neuroendocrine tumors, its role in cardiovascular disease states including essential hypertension (EH) has only recently been recognized. It acts as a prohormone giving rise to bioactive peptides such as vasostatin-I (human CHGA(1-76)) and catestatin (human CHGA(352-372)) that exhibit several cardiovascular regulatory functions. CHGA is over-expressed but catestatin is diminished in EH. Moreover, genetic variants in the promoter, catestatin, and 3'-untranslated regions of the human CHGA gene alter autonomic activity and blood pressure. Consistent with these findings, targeted ablation of this gene causes severe arterial hypertension and ventricular hypertrophy in mice. Transgenic expression of the human CHGA gene or exogenous administration of catestatin restores blood pressure in these mice. Thus, the accumulated evidence establishes CHGA as a novel susceptibility gene for EH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.